Mechanisms and strategies to overcome multiple drug resistance in cancer
Tóm tắt
One of the major problems in chemotherapy is multidrug resistance (MDR) against anticancer drugs. ATP‐binding cassette (ABC) transporters are a family of proteins that mediate MDR via ATP‐dependent drug efflux pumps. Many MDR inhibitors have been identified, but none of them have been proven clinically useful without side effects. Efforts continue to discover not toxic MDR inhibitors which lack pharmacokinetic interactions with anticancer drugs. Novel approaches have also been designed to inhibit or circumvent MDR. In this review, the structure and function of ABC transporters and development of MDR inhibitors are described briefly including various approaches to suppress MDR mechanisms.
Tài liệu tham khảo
10.1111/j.1365-2362.2004.01411.x
10.1186/1475-2867-5-22
Liscovitch M., 2002, Cancer multidrug resistance: a review of recent drug discovery research, IDrugs., 5, 349
10.1177/107327480301000207
10.1186/1475-2867-5-30
10.1146/annurev.pharmtox.39.1.361
10.1016/S0928-0987(00)00114-7
Stavrovskaya A.A., 2000, Cellular mechanisms of multidrug resistance of tumor cells, Biochemistry (Mosc)., 65, 95
10.1038/nrc706
10.1634/theoncologist.8-5-411
10.1101/gr.GR-1649R
10.2174/1566524013364194
10.1016/j.febslet.2004.03.123
10.1038/346362a0
10.1074/jbc.271.40.24617
10.1074/jbc.M211758200
Abolhoda A., 1999, Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin, Clin. Cancer Res., 5, 3352
10.1126/science.1360704
10.1073/pnas.95.26.15665
10.1016/0959-8049(96)00091-3
Ford J.M., 1990, Pharmacology of drugs that alter multidrug resistance in cancer, Pharmacol. Rev., 42, 155
10.1002/(SICI)1096-911X(200004)34:4<242::AID-MPO2>3.0.CO;2-U
Fischer V., 1998, The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A Implications for drug–drug interactions and pharmacological activity of the main metabolite, Drug Metab. Dispos., 26, 802
10.1023/A:1006487003814
10.1016/S0960-894X(99)00030-X
Newman M.J., 2000, Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance, Cancer Res., 60, 2964
Dantzig A.H., 1999, Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities, J. Pharmacol. Exp. Ther., 290, 854
10.1016/S0065-2571(96)00021-0
10.1016/0959-8049(96)00065-2
10.1074/jbc.275.10.7138
Lucci A., 1999, Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells, Int. J. Oncol., 15, 535
10.1074/jbc.271.32.19530
Lucci A., 1998, Glucosylceramide: a marker for multiple-drug resistant cancers, Anticancer Res., 18, 475
10.1074/jbc.274.2.1140
Lucci A., 1999, Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics, Int. J. Oncol., 15, 541
10.1074/jbc.272.3.1682
10.1002/(SICI)1097-0142(19990715)86:2<300::AID-CNCR14>3.0.CO;2-H
10.1093/jnci/93.5.347
Wilson W.H., 2000, Chemotherapy sensitization by rituximab: experimental and clinical evidence, Semin. Oncol., 27, 30
10.1016/j.febslet.2005.06.051
Kanadaswami C., 2005, The antitumor activities of flavonoids, In Vivo, 19, 895
10.1016/j.jss.2004.11.011
10.18388/abp.2005_3404